- Consort Medical Plc (CSRT) has entered into a development agreement with Regeneron Pharmaceuticals.
- The development agreement, which also includes key commercial supply terms provides for company’s proprietary VapourSoft technology to be unified into a novel drug delivery device designed by Regeneron.
- As per the agreement entered by the two companies, in the event of Regeneron deciding to go for commercialisation of the developed device, both the companies will enter into a full commercial supply agreement with manufacturing to be undertaken by Consort.
- On 18th October 2019, at the time of writing, GMT 08:02 AM, CSRT shares were trading at GBX 754.00, up by 4.00 points or 0.53% against the previous day closing price.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.